ED says Mumbai couple moved 80 kg of mephedrone a month; UAE pharmacies should check controlled stocks

India's Enforcement Directorate (ED) has filed a money-laundering complaint against Faisal Shaikh, Alifya Shaikh and 10 others over an alleged 80 kg monthly mephedrone supply operation in Mumbai, according to The Free Press Journal on 10 October 2026.

The highest-stakes readers are pharmacy COOs, insurer special investigations teams and medical directors. The case is outside the UAE, but the alleged Dubai link reported by FPJ makes it relevant to licensed pharmacies, clinics with controlled medicine cabinets and payers reviewing controlled-drug claims. In Dubai, the relevant regulator is the Dubai Health Authority (DHA). In Abu Dhabi and Al Ain it is the Department of Health Abu Dhabi (DOH). In Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, operators should check Ministry of Health and Prevention (MOHAP) rules and Emirates Drug Establishment (EDE) services where drug-control functions have transferred.

What ED alleges in Mumbai

FPJ reported that the ED submitted a prosecution complaint after an earlier Narcotics Control Bureau case. The report said the couple allegedly procured mephedrone from Salim Dola at Rs 7 lakh per kg and sold it at Rs 8 lakh per kg from 2022. At an indicative exchange rate of about INR 21.7 to AED 1, those figures equal roughly AED 32,000 to AED 37,000 per kg. That is an alleged illicit wholesale price, not a UAE clinical price.

The reported monthly volume, 80 kg, implies alleged gross sales of about Rs 6.4 crore, or roughly AED 2.9 million, before downstream street distribution. FPJ said ED has attached properties worth Rs 5.88 crore, about AED 2.7 million. FPJ also reported that NCB seized about 15 kg of MD, Rs 1.10 crore in cash, about Rs 29.93 lakh from lockers, and gold jewellery weighing about 845 grams.

Mephedrone is treated in India as a banned psychotropic substance under the Narcotic Drugs and Psychotropic Substances Act. FPJ reported that 50 grams is a commercial quantity under that law, while 2 grams is treated as a small quantity. UAE operators should avoid importing those thresholds into local policy. The UAE framework is separate, led by Federal Decree-Law No. 30 of 2021 on narcotics and psychotropic substances, referenced on the UAE Government portal.

The UAE pharmacy risk

For Dubai providers, the immediate operational reference is DHA's controlled-medication system. DHA issued circular CIR-2024-00000129 on 15 July 2024, announcing the National Platform for Controlled Medications inventory system and stating that controlled, semi-controlled and narcotic stock data had to move to the electronic register within one working week of activation on 22 July 2024.

That deadline matters because synthetic-drug cases rarely arrive as a neat clinical audit issue. They arrive as gaps in inventory, unexplained cash activity, suspicious repeat dispensing, identity misuse or payer exceptions. A Dubai pharmacy group should be able to reconcile controlled and semi-controlled stock by branch, pharmacist, prescriber and prescription reference. A clinic with a small medicine room should run the same test before DHA asks for it.

• Dubai: confirm Sheryan facility licensing, pharmacist privileges and NPCM stock reconciliation for every branch.
• Abu Dhabi and Al Ain: check DOH controlled-medicine standards, Emirates ID reader use and audit files for narcotic and controlled medicine workflows.
• Northern emirates: review MOHAP and EDE requirements for narcotic quotas, pharmacy licensing and personal medicine import permissions.
• Insurers: flag repeat controlled-drug claims, early refills, mismatched diagnosis codes and dispensing outside network rules.

For payers such as Daman, Thiqa and Sukoon, the case is a claims-integrity prompt rather than proof of UAE exposure. The useful action is to compare controlled-medicine claims against eligibility, prescriber licence status, pharmacy network status and refill intervals. Where a payer does not publish a specific threshold, the threshold should come from the policy schedule, the approved formulary and the regulator's controlled-drug rules.

What operators should do now

COOs should run a 30-day exception report on controlled and semi-controlled medicines by facility. CFOs should ask whether any pharmacy revenue line depends on products with weak documentation. Medical directors should check whether physicians understand the difference between prescription medicines, controlled medicines and prohibited substances for travellers and residents.

Patients need a simpler message. UAE Government guidance says narcotic and psychotropic substances are restricted unless handled through supervised medical or scientific channels under applicable law. The EDE personal medicine import service says travellers may obtain electronic approvals for controlled medications, with quantities tied to patient need and a maximum period stated in the service guidance. Patients should carry a prescription and should check the current controlled-medicine list before travel.

The commercial lesson is narrow. A cross-border trafficking complaint can become a UAE pharmacy audit problem if records are incomplete. UAE pharmacy providers should verify licences, branch details and patient-facing information through official regulator registries and the UAE Open Healthcare Directory, including its licensed pharmacy provider listings.